Melperone and extrapyramidal symptoms
Melperone has been reported to have a low extrapyramidal symptom (EPS) liability compared with typical/high-potency antipsychotics. [1] Clinical data in treatment of schizophrenia have reported no worsening of extrapyramidal symptoms during melperone use. [2]
Evidence from clinical studies
A study in neuroleptic-resistant schizophrenia reported that melperone was not associated with worsening of extrapyramidal symptoms during treatment. [2]
Evidence from comparative preclinical studies
In controlled trials in nonhuman primates, melperone was classified as having low EPS liability relative to typical neuroleptics, which produced acute EPS in the majority of patients in comparable settings. [1]
Clinical interpretation
Melperone can still cause drug-induced movement disorders, but the available evidence supports lower EPS risk than typical antipsychotics rather than absence of risk. [1]
Recognition of EPS for suspected melperone causality
Acute EPS syndromes include dystonia, akathisia, tremor, and parkinsonism. [3]
When to treat suspected melperone-induced EPS
Acute dystonic reactions are managed with prompt administration of an anticholinergic or antihistamine. [3]